Skip to content
Screener

Total Equity at other companies

Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$144M+49.5%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$61.31M-73.2%
Viatris logo
ViatrisVTRS
$14.26B-8.4%
AbbVie logo
AbbVieABBV
-$6.66B-569%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$448.66M+329%
Regenxbio logo
RegenxbioRGNX
$71.77M-66.4%

Other financials

Income statement

See full
Revenue$14.4M+65.7%
Gross profit$11.0M+117%
Operating income-$4.2M+78.3%
Net income-$8.1M+64.9%
EPS (diluted)-$0.07+70.8%

Balance sheet

See full
Cash & equivalents$110.7M+61.3%
Total debt$64.4M+7.4%
Total assets$141.1M+38.0%

Cash flow

See full
Operating cash flow-$14.8M+36.7%
CapEx$52.0K-61.5%
Free cash flow-$14.9M+36.9%

Valuation

See full
Market cap$494.34M+28.9%
Enterprise value$447.96M+17.1%
P/S9.8×+1.1×

Profitability

See full
Gross margin63.5%-4.9pp
Operating margin-111.2%+96.3pp
Net margin-137.1%+80.7pp
FCF margin-88.2%-2.2pp

Returns & leverage

See full
Return on equity145.1%
Debt / equity-1.9×
Current ratio4.1×-0.8×

Where this comes from

Reported directly by Aquestive Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001398733-26-000030
Line itemMarch 31,2026December 31,2025
Total liabilities175,179194,087
Contingencies (Note 20)
Stockholders’ deficit:
Common stock, $0.001 par value. Authorized 250,000,000 shares; 124,284,542 and 122,044,299 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively124122
Additional paid-in capital420,877413,214
Accumulated deficit(455,055)(446,998)
Total stockholders’ deficit(34,054)(33,662)
Total liabilities and stockholders’ deficit$141,125$160,425

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Aquestive Therapeutics, Inc.'s total equity?
Aquestive Therapeutics, Inc. (AQST) reported total equity of -$34.05M in Q1 2026.
How has Aquestive Therapeutics, Inc.'s total equity changed year-over-year?
Aquestive Therapeutics, Inc.'s total equity increased by 44.1% year-over-year, from -$60.93M to -$34.05M.
What is the long-term trend for Aquestive Therapeutics, Inc.'s total equity?
Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s total equity has grown at a -7.0% compound annual growth rate (CAGR), from -$48.5M to -$33.66M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Aquestive Therapeutics, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude